| Adaptive Hypofractionated Radiotherapy for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adebrelimab for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AK105 and anlotinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anti-PD-1 monoclonal antibody + LCB84 for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| B1962 for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brachytherapy + External Beam Radiotherapy (EBRT) + NIMOTUZUMAB + CISPLATIN for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brachytherapy + External Beam Radiotherapy (EBRT) + placebo for Nimotuzumab + CISPLATIN for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cadonilimab for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| camrelizumab; famitinib malate for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capivasertib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + NAB-PACLITAXEL for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy + FAMITINIB L-MALATE + CAMRELIZUMAB for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy + Hypofractionated external beam radiation + Image-guided brachytherapy for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| concurrent chemotherapy + Definitive hypofractionated intensity-modulated radiation theraphy for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + Tersolisib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Gecacitinib + ZG005 + BEVACIZUMAB for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GT101 + HUMAN INTERLEUKIN-2 for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| High Dose Rate Brachytherapy + intra-lesional boost IMRT for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| JSKN033 + BEVACIZUMAB + PLATINUM for uterine cervical neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LCB84 for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| paclitaxel combined with platinum for uterine cervical neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Patritumab Deruxtecan for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| radical surgery + CAMRELIZUMAB + Paclitaxel + CISPLATIN for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab govitecan for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Sacituzumab tirumotecan for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Serplulimab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SHR-A1811 Injection for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sigvotatug Vedotin for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tersolisib for uterine cervical neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tretinoin for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for uterine cervical neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|